YCYe Cheng

Ye Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ye Cheng has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Jian-She Wang

    The Center for Pediatric Liver Diseases, Children’s Hospital of Fudan University, Shanghai, China

    4 shared publications
  • Qinghe Xing

    Children’s Hospital of Fudan University and Institutes of Biomedical Sciences of Fudan University, Shanghai, China

    3 shared publications
  • Changlian Zhu

    Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Institute of Neuroscience, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Hongwei Li

    Department of Pediatrics, Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, The Third Affiliated Hospital and Institute of Neuroscience of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Jin Zhang

    Children’s Hospital of Fudan University and Institutes of Biomedical Sciences of Fudan University, Shanghai, China

    2 shared publications
  • Li Wang

    The Center for Pediatric Liver Diseases, Children’s Hospital of Fudan University, Shanghai, China

    2 shared publications

Latest Publications

  • Liver transcriptome sequencing contributes to the molecular diagnosis of genetic liver diseases

    by Ye Cheng, Zhong-Die Li, Zhi-Hong Guan, Li Wang, Yi-Ling Qiu, Wei-Yuan Fang, Jing Zhao, Kun Zhang, Jia-Qi Li, Qing-He Xing, et al.

    Background & Aims: Since DNA sequencing alone faces challenges in variant interpretation during genetic diagnosis, RNA sequencing has recently gained attention in resolving these diagnostic gaps. This study aimed to evaluate the advantages of liver tissue RNA sequencing in the diagnosis of genetic liver diseases. Approach & Result: Liver tissue RNA sequencing was performed on 147 patients with prior DNA sequencing. We evaluated the role of RNA sequencing by analyzing aberrant gene expression, splicing, allele-specific expression, transcript-level similarity and mosaic variants. Liver RNA-seq supported the molecular diagnoses in 56 patients diagnosed by DNA sequencing alone. Among 91 previously undiagnosed patients, incorporating RNA sequencing established a diagnosis in 17 (18.68%) patients. Among the 33 patients with indicative clinical phenotypes or prioritized variants, diagnosis was established in 15 (45.45%) patients under the help of RNA sequencing. This improvement was primarily (16/17) driven by the detection of aberrant splicing and allele-specific expression, instead of aberrant expression. RNA sequencing revealed ±50bp of cryptic splicing sites as hotspot regions, characterized allele-specific expression at both the gene and variant levels and revealed shared transcriptomic features in low GGT cholestasis. Conclusions: While DNA sequencing demonstrates superior sensitivity in detecting clinically relevant variants, liver RNA sequencing significantly enhances genetic diagnosis mainly by revealing aberrant splicing and allele-specific expression. These findings suggest that RNA sequencing is an essential complement to DNA sequencing. Export


  • Top Cited Papers

    Exome sequencing reveals genetic heterogeneity and clinically actionable findings in children with cerebral palsy

    by Yangong Wang, Yiran Xu, Chongchen Zhou, Ye Cheng, Niu Qiao, Qing Shang, Lei Xia, Juan Song, Chao Gao, Yimeng Qiao, et al.

    Cerebral palsy (CP) is the most common motor disability in children. To ascertain the role of major genetic variants in the etiology of CP, we conducted exome sequencing on a large-scale cohort with clinical manifestations of CP. The study cohort comprised 505 girls and 1,073 boys. Utilizing the current gold standard in genetic diagnostics, 387 of these 1,578 children (24.5%) received genetic diagnoses. We identified 412 pathogenic and likely pathogenic (P/LP) variants across 219 genes associated with neurodevelopmental disorders, and 59 P/LP copy number variants. The genetic diagnostic rate of children with CP labeled at birth with perinatal asphyxia was higher than the rate in children without asphyxia (P = 0.0033). Also, 33 children with CP manifestations (8.5%, 33 of 387) had findings that were clinically actionable. These results highlight the need for early genetic testing in children with CP, especially those with risk factors like perinatal asphyxia, to enable evidence-based medical decision-making.


  • Open Access

    Transcript selection for the genetic diagnosis of KIF12-associated progressive familial intrahepatic cholestasis

    by Ye Cheng, Yi-Qiong Zhang, Bing-Xuan Wei, Lian Chen, Qing-He Xing, Jian-She Wang

    Cholestatic jaundice in infancy occurs in ∼1 in 2,500 term infants and 25% of cases are genetically determined [ 1]. An accurate diagnosis is crucial for clinicians to provide timely and personalized management. Despite the increasing application of whole-exome sequencing (WES), the genetic diagnosis of some patients remains unclear.


  • Open Access

    Splicing Analysis of MYO5B Noncanonical Variants in Patients with Low Gamma-Glutamyltransferase Cholestasis

    by Li Wang, Yi-Ling Qiu, Kuerbanjiang Abuduxikuer, Neng-Li Wang, Zhong-Die Li, Ye Cheng, Yi Lu, Xin-Bao Xie, Qing-He Xing, Jian-She Wang

    Biallelic MYO5B variants have been associated with familial intrahepatic cholestasis (FIC) with low serum gamma-glutamyltransferase (GGT). Intronic or synonymous variants outside of canonical splice sites (hereinafter referred to as noncanonical variants) with uncertain significance were identified in MYO5B posing a challenge in clinical interpretation. This study is aimed at assessing the effects of these variants on premessenger RNA (pre-mRNA) splicing to improve recognition of pathogenic spliceogenic variants in MYO5B and better characterize the MYO5B genetic variation spectrum. Disease-associated MYO5B noncanonical variants were collected from the literature or newly identified low GGT cholestasis patients. In silico splicing predictions were performed to prioritize potential pathogenic variants. Minigene splicing assays were performed to determine their splicing patterns, with confirmation by blood RNA analysis in one case. Eleven (five novel) noncanonical variants with uncertain significance were identified. Minigene splicing assays revealed that three variants (c.2090+3AT, c.2414+5GT, and c.613-11GA) caused complete aberrations, five variants (c.2349AG/p.(=), c.4221GA/p.(=), c.1322+5GA, c.1669-35AC, and c.3045+3AT) caused predominant aberrations, and three variants (c.4852+11AG, c.455+8TC, and c.2415-6CG) had no effect on pre-mRNA splicing. Patient-derived RNA analysis showed consistent results. Based on our results, eight variants were reclassified as likely pathogenic and three as likely benign. Combining the clinical features and the above analysis, the diagnosis of MYO5B-associated FIC could be made in three new patients. In conclusion, we characterized the splicing patterns of MYO5B noncanonical variants and suggest that RNA analysis should be routinely included in clinical diagnostics to provide essential evidence for the interpretation of variants.

  • Recurrent AKR1D1 c.580-13T>A Variant

    by Jing Zhao, Yi-Ling Qiu, Li Wang, Zhong-Die Li, Xin-Bao Xie, Yi Lu, Kenneth D.R. Setchell, Ye Cheng, Qing-He Xing, Jian-She Wang


  • Open Access

    Exome-wide association study identified genetic variants contributing to the risk of cerebral palsy

    by Qinghe Xing, Ye Cheng, Yiran Xu, Hongwei Li, Yimeng Qiao, Yangong Wang, Yu Su, Jin Zhang, Xiaoyang Wang, Changlian Zhu

    Cerebral palsy (CP) is the most common physical disability in childhood that results from the interaction of environmental and genetic factors. Yet in many patients, the etiology remains unknown. We identified significant association at rs3131787 within the human leukocyte antigen (HLA) region using two-stage association study between 1,090 CP cases and 1,100 controls. Fine mapping of the HLA region indicated that the carrier frequency of HLA-B*13:02 was significantly higher in CP, particularly in CP without preterm birth, low birth weight, birth asphyxia or periventricular leukomalacia (PVL). DRB1*07:01/DQA1*02:01 was also significantly enriched in CP and more specifically in dyskinetic type. Additionally, significant enrichment of carrier frequency was detected for HLA-A*32:01 in CP with either preterm birth or low birth weight and for HLA-B*27:05 in CP with birth asphyxia. These data suggest that immune dysregulation resulting from immunogenetic variants or environmental exposures may underlie the pathogenesis of CP.